BCM
BMRN icon

BBT Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

BBT Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-25,000
Closed -$1.76M – 269
2013
Q4 		$1.76M Buy
+25,000
New +$1.7M 0.08% 211

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBT Capital Management's BMRN Position: Q3 2014 in Review

BBT Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2014, closing a stake of 55,441 shares — an estimated $3.45M sold.

BBT Capital Management first reported a position in BMRN in Q4 2013 and held it in 3 quarters. The position peaked at $4.01M in Q1 2014. 316 funds tracked by Wall St. Rank hold BMRN as of Q3 2014.

  • BBT Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • BBT Capital Management sold 55,441 BioMarin Pharmaceuticals shares in Q3 2014, an estimated $3.45M.
  • BBT Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • BBT Capital Management's BioMarin Pharmaceuticals position peaked at $4.01M in Q1 2014.
  • 316 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2014.

Based on BBT Capital Management's 13F filing for Q3 2014, filed 12 Nov 2014.